New York State Common Retirement Fund Has $150.76 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

New York State Common Retirement Fund reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,632,088 shares of the biopharmaceutical company's stock after selling 80,477 shares during the quarter. New York State Common Retirement Fund owned 0.13% of Gilead Sciences worth $150,756,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the third quarter valued at about $25,000. HHM Wealth Advisors LLC raised its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the period. Valued Wealth Advisors LLC raised its position in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 161 shares during the period. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $29,000. 83.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Maxim Group lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Oppenheimer increased their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, December 10th. Daiwa America raised shares of Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Barclays upped their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an "equal weight" rating in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group upped their price target on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $102.08.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the sale, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock worth $67,945,181 in the last ninety days. Company insiders own 0.16% of the company's stock.

Gilead Sciences Price Performance

Shares of GILD traded down $0.08 during mid-day trading on Friday, reaching $109.95. The company had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. The company's 50 day simple moving average is $95.41 and its 200 day simple moving average is $88.73. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $111.03. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $137.03 billion, a price-to-earnings ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is currently 832.43%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.